Domů › Leukémie › Massachusetts › Boston
Klinické studie Leukémie v Boston, MA
25 studií pro Leukémie hledá účastníky v lokalitách v Boston a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Probíhá náborFáze 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Probíhá nábor
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Probíhá náborFáze 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Probíhá náborFáze 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Probíhá náborFáze 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Probíhá náborFáze 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
Probíhá náborFáze 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Probíhá nábor
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Probíhá náborVítáni zdraví dobrovolníci
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Probíhá náborFáze 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Probíhá náborFáze 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Probíhá náborObservační studie
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Probíhá nábor
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
Probíhá náborObservační studie
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Probíhá náborFáze 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Probíhá náborFáze 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Probíhá náborFáze 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Probíhá nábor
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Probíhá nábor
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studie Leukémie v jiných městech
- Houston, TX28 studií
- New York City, NY19 studií
- Los Angeles, CA16 studií
- Chicago, IL16 studií
- Durham, NC13 studií
- Columbus, OH12 studií
- Nashville, TN12 studií
- Baldwin Park, CA12 studií
- Philadelphia, PA12 studií
- Milwaukee, WI11 studií
- Atlanta, GA11 studií
- Seattle, WA11 studií
Další studie v Boston
- Rakovina prsu111 studií
- Nemalobuněčný plicní karcinom90 studií
- Rakovina (všechny typy)86 studií
- Kolorektální karcinom63 studií
- Metastatický karcinom63 studií
- Rakovina plic62 studií
- Rakovina vaječníků61 studií
- Rakovina prostaty59 studií
- Deprese52 studií
- Rakovina endometria50 studií
- Srdeční selhání44 studií
- Akutní myeloidní leukemie44 studií
Zdroj: ClinicalTrials.gov, data načtena 4. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.